Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00528437 · ClinicalTrials.gov registry record · Phase 2
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00528437 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 46 participants.
The verdict
NCT00528437, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to: Find out how safe and effective (by monitoring the good and/or bad effects) treatment with high dose temozolomide, thiotepa and carboplatin with stem cell rescue followed by 13-cis-retinoic acid has on children and adolescents with recurrent/refractory brain tumors Find out how the body uses 13-cis-retinoic acid by studying the your blood levels and proteins in the blood that break down the 13-cis-retinoic acid Determine how well 13-cis-retinoic acid penetrates into the spinal fluid.
Interventions
- DRUG temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2005-10 |
| Est. Completion | 2017-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00528437
The ClinicalTrials.gov registry entry for NCT00528437 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid is the first listed.
NCT00528437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00528437 about?
NCT00528437 is a clinical study titled "Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors". The purpose of this study is to: Find out how safe and effective (by monitoring the good and/or bad effects) treatment with high dose temozolomide, thiotepa and carboplatin with stem cell rescue followed by 13-cis-retinoic acid has on children and adolescents with recurrent/refractory brain tumors ...
What is the current status of trial NCT00528437?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2005-10. Estimated completion is 2017-12-30.
What interventions are being tested in trial NCT00528437?
The interventions under investigation include: temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid (DRUG).
Who is sponsoring clinical trial NCT00528437?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.